Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WRAIR-PAM-CF1 in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa
NCT05453578Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2022
- Primary completion
- Apr 2025
- Modality
- Implantable Devices, Transdermal Patches, Single Strain Products
- Countries
- 1
01
Overview
A Phase 2 trial of WRAIR-PAM-CF1 in Pseudomonas aeruginosa infection, sponsored by National Institute of Allergy and Infectious Diseases. Started Oct 2022; status: completed.
02
Drugs
WRAIR-PAM-CF1
03
Conditions
Pseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT05453578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05453578.